Ascletis Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,444	865.73	330.12	403.77	2,495
Short-Term Investments	431.26	1,079	1,948	2,070	2.59
Trading Asset Securities	26.1	7.37	24.83	11.2	5.2
Cash & Short-Term Investments	1,901	1,953	2,303	2,485	2,503
Cash Growth	-2.65%	-15.23%	-7.30%	-0.74%	-7.84%
Accounts Receivable	0.22	0.15	5.43	23.87	53.61
Other Receivables	-	9.11	12.85	5.4	13.79
Receivables	0.22	9.26	18.28	29.27	67.39
Inventory	1.87	4.37	6.07	20.52	56.23
Prepaid Expenses	-	1.01	1.03	2.13	2.3
Other Current Assets	17.75	3.62	4.13	8.13	2.34
Total Current Assets	1,921	1,971	2,333	2,545	2,632
Property, Plant & Equipment	46.7	57.07	68.28	71.83	77.51
Long-Term Investments	88.1	84.39	63.02	22.02	41.86
Other Intangible Assets	10.29	12.12	26.32	16.56	78.21
Long-Term Deferred Charges	0.46	0.08	0.38	0.7	0.42
Other Long-Term Assets	0.26	0.13	0.26	1.22	0.41
Total Assets	2,067	2,125	2,491	2,657	2,830
Accounts Payable	1.34	0.03	0.65	3.14	1.05
Accrued Expenses	-	83.8	91.87	56.15	52.29
Current Portion of Leases	2.87	6.25	5.71	2.42	1.57
Current Unearned Revenue	1.59	1.98	1.59	1.97	1.59
Other Current Liabilities	121.79	61	40.86	44.52	34.47
Total Current Liabilities	127.59	153.05	140.68	108.19	90.97
Long-Term Leases	2.29	1.39	2.71	1.82	1.18
Long-Term Unearned Revenue	2.38	3.97	5.56	7.15	8.73
Total Liabilities	132.26	158.41	148.94	117.16	100.89
Common Stock	0.68	0.69	0.73	0.74	0.75
Additional Paid-In Capital	-	2,750	2,843	2,867	2,884
Retained Earnings	-	-1,475	-1,174	-1,030	-714.85
Treasury Stock	-	-56.7	-51.95	-	-18.71
Comprehensive Income & Other	1,934	747.55	724.56	702	578.32
Total Common Equity	1,934	1,966	2,342	2,540	2,729
Shareholders' Equity	1,934	1,966	2,342	2,540	2,729
Total Liabilities & Equity	2,067	2,125	2,491	2,657	2,830
Total Debt	5.16	7.63	8.42	4.24	2.75
Net Cash (Debt)	1,896	1,945	2,295	2,480	2,501
Net Cash Growth	-2.53%	-15.25%	-7.48%	-0.80%	-7.89%
Net Cash Per Share	1.95	1.94	2.14	2.28	2.28
Filing Date Shares Outstanding	982.25	971.07	1,061	1,087	1,096
Total Common Shares Outstanding	982.25	971.07	1,061	1,087	1,096
Working Capital	1,793	1,818	2,192	2,437	2,541
Book Value Per Share	1.97	2.02	2.21	2.34	2.49
Tangible Book Value	1,924	1,954	2,316	2,523	2,651
Tangible Book Value Per Share	1.96	2.01	2.18	2.32	2.42
Machinery	-	127.38	126.13	121.54	115.33
Construction In Progress	-	-	-	-	0.03
Leasehold Improvements	-	2.87	2.87	2.87	2.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.